Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $54.03 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +48.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $11.36 million | Q1 2018: $8.76 million | Q2 2018: $40.41 million | Q3 2018: $15.20 million | Q4 2018: $30.01 million | Q1 2019: $30.23 million | Q2 2019: $26.22 million | Q3 2019: $26.02 million | Q4 2019: $35.44 million | Q1 2020: $87.10 million | Q2 2020: $37.35 million | Q3 2020: $34.71 million | Q4 2020: $44.05 million | Q1 2021: $0.00 | Q2 2021: $0.00 | Q3 2021: $0.00 | Q1 2022: $832.0 thousand | Q2 2022: $5.58 million | Q3 2022: $3.52 million | Q1 2023: $5.61 million | Q2 2023: $6.71 million | Q3 2023: $7.40 million | Q1 2024: $8.19 million | Q2 2024: $8.62 million | Q3 2024: $8.96 million | Q1 2025: $8.73 million | Q2 2025: $12.46 million | Q3 2025: $12.88 million.
- Over the full 10 years of available data (2016 to 2025), AGIOS PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 22.7%.
- Historical annual values: Fiscal year 2025: $54.03 million | Fiscal year 2024: $36.50 million | Fiscal year 2023: $26.82 million | Fiscal year 2022: $14.24 million | Fiscal year 2021: $0.00 | Fiscal year 2020: $0.00 | Fiscal year 2019: $117.91 million | Fiscal year 2018: $94.39 million | Fiscal year 2017: $43.01 million | Fiscal year 2016: $69.89 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: